secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-07-20T11:13:05+00:00
Accession:  0001104659-26-084861
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharmaceuticals Reports Progress on AP-SA02 Phase 3 Study and Promotes David House to CFO
--------------------------------------------------------------------------------

- Submitted complete Phase 3 superiority protocol to FDA for AP-SA02, addressing all End-of-Phase 2 meeting comments.
- Completed four engineering runs of AP-SA02 at cGMP facility; clinical trial material production is next step.
- Received $2.5 million continuation award from DoD, bringing total funding to $28.7 million for Phase 3 readiness.
- Promoted David House to Chief Financial Officer; he previously served as SVP, Finance since August 2024.
- Phase 3 superiority study remains on track to initiate in the second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/0001104659-26-084861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer